GlassScriptPhysician profile
Rajivi Rucker
NPI 1194721522
$11,506.74
in general payments reported to CMS, 2019-2025
38 companies · $2,815 in 2025
The $2,815 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $845 · 2020: $787 · 2021: $1,126 · 2022: $1,900 · 2023: $2,147 · 2024: $1,886 · 2025: $2,815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,684 · Education: $94.66 · Consulting Fee: $69.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,684.17 |
| Education | $94.66 |
| Consulting Fee | $69.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,697.64 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,693.99 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,309.88 | 2020-2025 | |
| Csl Behring | $1,063.18 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Regeneron Healthcare Solutions, INC. | $859.09 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $687.41 | 2020-2025 | Hyqvia, Cuvitru, Takhzyro |
| Pfizer INC. | $504.43 | 2021-2025 | |
| Amgen INC. | $468.80 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $448.34 | 2019-2025 | |
| Octapharma USA, INC. | $359.71 | 2019-2022 | |
| Kaleo, INC. | $293.44 | 2019-2023 | Auvi-Q |
| Genentech USA, INC. | $278.05 | 2020-2025 | Xolair |
| Biocryst US Sales Co., LLC | $195.97 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $184.26 | 2020-2025 | Ruconest |
| Grifols USA, LLC | $182.56 | 2020-2025 | Xembify |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $177.15 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $149.30 | 2020-2022 | |
| Shire North American Group INC | $115.72 | 2019 | |
| Ionis Pharmaceuticals, INC. | $97.64 | 2025 | Dawnzera |
| Blueprint Medicines Corporation | $83.31 | 2023-2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.15 | 2020-2021 | |
| Adma Biomanufacturing LLC | $69.39 | 2024-2025 | |
| Lilly USA, LLC | $66.80 | 2025 | Ebglyss |
| Abbvie INC. | $50.95 | 2022-2024 | |
| Galderma Laboratories, L.P. | $49.76 | 2025 | Nemluvio |
| Teva Pharmaceuticals USA, INC. | $45.99 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $44.85 | 2025 | Neffy |
| Alk-Abello, INC | $37.21 | 2022 | |
| Horizon Therapeutics Plc | $28.69 | 2021 | |
| Azurity Pharmaceuticals, INC. | $26.27 | 2025 | Alvesco |
| Incyte Corporation | $26.25 | 2022 | |
| Gc Biopharma USA, INC. | $24.14 | 2025 | Alyglo |
| Leo Pharma INC. | $23.89 | 2022 | |
| Paratek Pharmaceuticals, INC. | $23.40 | 2025 | Xhance |
| Hikma Pharmaceuticals USA | $17.07 | 2023 | Ryaltris |
| Phadia US INC. | $16.15 | 2022 | |
| Merck Sharp & Dohme LLC | $14.50 | 2021 | |
| Circassia INC. | $13.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajivi Rucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.